Clinical Trial Update: A Study of Venetoclax and ABBV-838 Combination Therapy With Dexamethasone in Participants With Multiple Myeloma Whose Cancer Has Come Back or Had No Response to Recent Cancer Treatment [Phase 1]

View source ↗

Summary

This document notes the withdrawal of a Phase 1 clinical trial evaluating a combination of venetoclax and ABBV-838 with dexamethasone in participants with relap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• ABBV-838 (ABBV-838)
• DEXAMETHASONE (Dexamethasone)
• Venclyxto (Venetoclax)

Snippet

Sponsor: AbbVie | Conditions: Multiple Myeloma | Phase 1 | Status: WITHDRAWN